{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.33","value":"16.7"},{"groupId":"OG001","spread":"2.16","value":"17.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"265"},{"groupId":"OG001","value":"117"}],"units":"Participants"}],"title":"Respiration Rate: Baseline (Actual)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.32","value":"16.6"},{"groupId":"OG001","spread":"2.28","value":"17.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"260"},{"groupId":"OG001","value":"114"}],"units":"Participants"}],"title":"Respiration Rate: Post-dosing (Actual)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.03","value":"-0.1"},{"groupId":"OG001","spread":"2.00","value":"0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"260"},{"groupId":"OG001","value":"114"}],"units":"Participants"}],"title":"Respiration Rate: Change from Baseline"}],"denoms":[{"counts":[{"groupId":"OG000","value":"265"},{"groupId":"OG001","value":"117"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"High risk prostate cancer participants planned for radical prostatectomy with pelvic lymph node dissection (Cohort A) were enrolled to receive a single dose of 9 mCi (333 MBq) IV injection of 18F-DCFPyL, followed by PET/CT imaging acquired 1-2 hours post-PyL injection.","id":"OG000","title":"High Risk Prostate Cancer (Cohort A)"},{"description":"Participants with presumptive radiologic evidence of prostate cancer recurrence or metastasis on conventional imaging and planned for conventional image-guided biopsy (Cohort B) were enrolled to receive a single dose of 9 mCi (333 MBq) IV injection of 18F-DCFPyL, followed by PET/CT imaging acquired 1-2 hours post-PyL injection.","id":"OG001","title":"Recurrent or Metastatic Prostate Cancer (Cohort B)"}],"paramType":"MEAN","populationDescription":"The Safety Set includes all participants who received any amount of 18F-DCFPyL and have reported data (i.e., some participants had missing vital sign measurements).","reportingStatus":"POSTED","timeFrame":"Measured at two intervals on the day of dosing, pre-dosing (baseline) and post-dosing/pre-imaging.","title":"Mean Change From Baseline in Respiration Rate Post 18F-DCFPyL Dosing (Safety Outcome Measure)","type":"SECONDARY","unitOfMeasure":"breaths per minute"}